Format

Send to

Choose Destination
Tob Induc Dis. 2019 Apr 5;17:26. doi: 10.18332/tid/105579. eCollection 2019.

Secondary analysis of an RCT on Emergency Department-Initiated Tobacco Control: Repeatedly assessed point-prevalence abstinence up to 12 months and extension of results through a 10-year follow-up.

Author information

1
Department of Anesthesiology and Intensive Care Medicine, Charité- Universitätsmedizin Berlin, Berlin, Germany.
2
Center for Cancer Prevention and Control Research, UCLA Fielding School of Public Health, Los Angeles, United States.
3
Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany.

Abstract

INTRODUCTION:

Emergency departments (EDs) are opportune places for tobacco control interventions. The 'Tobacco Control in an Urban Emergency Department' (TED) study, ISRCTN41527831, originally evaluated the effect of motivational interviewing on-site plus up to four booster telephone calls on 12-month abstinence. This study's aim was to evaluate the effect of the intervention on 7-day point-prevalence abstinence at 10 years follow-up (primary outcome) as well as on repeated point-prevalence abstinence at 1, 3, 6, 12 months and at 10 years (continual smoking abstinence, secondary outcome).

METHODS:

At the 10 years follow-up and after informed consent, study participants responded to a mailed questionnaire. The primary outcome was analyzed in observed-only and in all-cases analyses. The secondary outcomes were analyzed using a multiple adjusted GLMM for binary outcomes.

RESULTS:

Out of 1012 TED-study participants, 986 (97.4%) were alive and 231 (23.4% of 986) responded to the follow-up at 10 years. For observed-only and all-cases analyses, the effect of the baseline intervention on 7-day point-prevalence abstinence at the 10 years follow-up was statistically non-significant. However, when taking into account all repeated measures, the intervention significantly influenced continual abstinence with odds ratio 1.32 (95% CI: 1.01-1.73; p=0.042). Baseline motivation, perceived self-efficacy to stop smoking, and nicotine dependency were independently associated with long-term continual smoking abstinence (all p<0.05).

CONCLUSIONS:

A conventional analysis failed to confirm a significant effect of the ED-initiated tobacco control intervention on the point-prevalence abstinence at 10 years. Results from a more integrative analysis nonetheless indicated an enduring intervention effect on continual abstinence among smokers first encountered in the emergency department setting 10 years earlier.

KEYWORDS:

emergency service; hospital; long-term follow-up; tobacco use cessation

Conflict of interest statement

The authors declare that they have no competing interests, financial or otherwise, related to the current work. C Spies received funding from Deutsche Krebshilfe (DKH-111507) during the conduct of the present work. C Spies also received funding outside the present work from European Union Seventh Framework research program [FP7/2007-2013], under the grant agreement No. HEALTH-F2-2014-60246, Continued BioCog. C Spies reports grants outside this work from: Dr F. Köhler Chemie GmbH, AppAdventure, J&P Medical Research Ltd., Pharmaceutical Research Associates GmbH, Delcath Systems Inc., INC Research UK Ltd., La Jolla Pharmaceutical Company, Aridis Pharmaceutical Inc., B. Braun Melsungen AG, Drägerwerk AG & Co. KGaA, Grünenthal GmbH, Infectopharm GmbH, Sedana Medical Ltd., Arbeitsgemeinschaft industrieller Forschungsvereinigungen ‘Otto von Guericke’ e.V., Berufsverband Deutscher Anästhesisten e.V., Deutsche Forschungsgemeinschaft, Deutsches Zentrum für Luftund Raumfahrt e.V., Einstein Stiftung Berlin, European Society of Anaesthesiology, Gemeinsamer Bundesausschuss, Inneruniversitäre Forschungsförderung, Projektträger im DLR, Stifterverband, WHOCC, Westfälische Wilhelms-Universität Münster/DFG, AbbVie Deutschland GmbH & Co. KG, Aguettant Deutschland GmbH, MAQUET Vertrieb und Service Deutschland GmbH, Orion Pharma GmbH, Philips Electronics Nederland B.V., Sintetica GmbH, Baxter Deutschland GmbH, Biotest AG, Cytosorbents Europe GmbH, Edwards Lifesciences Germany GmbH, Fresenius Medical Care, Grünenthal GmbH, Masimo Europe Ltd., Medtronic GmbH, Pfizer Pharma PFE GmbH, European Commission, Bundesministerium für Umwelt, Naturschutz und nukleare Sicherheit. C Spies also reports personal fees from Georg Thieme Verlag outside this work. In addition, C Spies has a patent 10 2014 215 211.9 pending, a patent Application No. PCT/EP2015/067730 pending to Graft Gesellschaft von Architekten mbH, and a patent Application No. PCT/ EP2015/067731 pending to Graft Gesellschaft von Architekten mbH. The rest of the authors have also completed and submitted an ICMJE form for disclosure of potential conflicts of interest.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center